A robust immune response against SARS-CoV-2 requires two phases, neutralization and effector T-cell functions, and the BNT162b2 vaccine effectively induces both humoral and cell-mediated immune responses in anti-PD 1/PDL-1-treated cancer patients. This evidence concerns the gene RPL17 and cancer.